[Skip to Content]
[Skip to Content Landing]
Medical News and Perspectives
November 2, 2005

Experts Ponder Pediatric Research Ethics

JAMA. 2005;294(17):2148-2151. doi:10.1001/jama.294.17.2148

More than a quarter century ago, pediatrician Harry Shirkey, MD, of Children’s Hospital in Birmingham, Ala, described infants and children as “therapeutic or pharmaceutical orphans” because relatively few drugs had been explicitly studied in pediatric patients (Shirkey. J Pediatr. 1968;72:119-120). Although the problem is well recognized, addressing it is no easy feat because of one incontrovertible truth: children cannot be protected from all research-related risks if they also are to benefit from medical treatments that can ameliorate or cure diseases. At some point, a child will be the first to receive a new drug or other therapy, so a delicate balance must be maintained between advancing knowledge that can help children and ensuring that risks are minimal and reasonable.

First Page Preview View Large
First page PDF preview
First page PDF preview